According to the company’s exchange filing, the transaction values Pivot Path at approximately ₹2,300 million (~₹230 crore) on a post-money basis. As part of the transaction, Strides Pharma Science will realise approximately ₹1,000 million (~₹100 crore) and will retain approximately a 20% stake in Pivot Path.
The transaction also includes a primary capital infusion of ₹500 million (~₹50 crore) into Pivot Path to support its growth and technology development initiatives.
Following completion of the transaction, Pivot Path will be reclassified as an associate of Strides Pharma Science.
Pivot Path was carved out from Arco Lab Private Limited, Strides’ Global Capability Centre, pursuant to a Scheme of Arrangement approved by the National Company Law Tribunal (NCLT) in May 2026. Pivot Path has been built as a technology-enabled platform offering life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services.
For FY26, the carved-out business reported revenue of ₹1,447 million and EBITDA of ₹169 million, as per the press release. Pivot Path focuses on delivering consulting, digital innovation, compliance, and operational services for pharmaceutical and manufacturing companies.
Also Read: IIFL Finance plans ₹10,000 crore fund raise; board also ups borrowing limits
